Radioembolisation (TARE / SIRT, yttrium-90)
Millions of tiny radioactive glass or resin beads are injected into the liver artery, lodging in the tumour and irradiating it from within.
Overview
Yttrium-90 microspheres (TheraSphere glass, SIR-Spheres resin) deliver beta radiation to hepatic tumours. Randomised trials versus sorafenib in advanced HCC (SARAH, SIRveNIB) were negative for OS but showed better tolerability and response; personalised dosimetry (DOSISPHERE-01) and radiation segmentectomy (LEGACY) established curative-intent use in early-stage disease. Standard alternative to TACE and a bridge or downstaging tool to transplant.
How it works
Arterial delivery of 20-60 µm microspheres carrying 90Y (beta emitter, 2.5 mm mean path, 64 h half-life); dose planned from 99mTc-MAA mapping and lung shunt fraction.
- Outpatient, single session
- Effective in portal vein thrombosis where TACE is contraindicated
- Radiation segmentectomy can be curative for small tumours
- Radioembolisation-induced liver disease
- Failed to beat sorafenib on OS in advanced disease
- Lung shunting excludes some patients
Tiny plastic beads carrying a radioactive, slightly magnetic metal are injected into the artery feeding a liver tumour. Because the metal shows up on both nuclear scans and MRI, doctors can check exactly where the beads went.
Tiny clumps of albumin, a normal blood protein, tagged with a radioactive marker and injected into a vein. They wedge briefly in the smallest blood vessels of the lung wherever blood is flowing, so the scan maps the lung's blood supply; the clumps then break up and clear.
Microscopic glass beads containing a radioactive metal are injected into the artery that supplies a liver tumour. The beads stay in place permanently and give off radiation that fades away within about two weeks.
Tiny radioactive beads are injected through a small tube into the artery that feeds the liver. They lodge in the tumour and give it radiation from the inside, mostly sparing the rest of the liver.
Latest papers
topQuery for this technology: (TITLE:"Radioembolisation" OR ABSTRACT:"Radioembolisation" OR TITLE:"TARE / SIRT, yttrium-90" OR ABSTRACT:"TARE / SIRT, yttrium-90") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Radioembolisation (TARE / SIRT, yttrium-90), not a curated reading list.
Similar pages
not linked directly; found by shared links- TrialTheraSphere With Durvalumab and Tremelimumab for HCC
Shares Boston Scientific, Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma, Hepatocellular carcinoma, Yttrium-90.
- TermTARE / SIRT (radioembolisation with yttrium-90)
Shares Quirem Medical, Hepatocellular carcinoma, Yttrium-90, Neuroendocrine tumours.
- AgentSorafenib
Shares SARAH and SIRveNIB, Radioembolisation (TARE) compared with sorafenib in hepatocellular carcinoma, Hepatocellular carcinoma.
- AgentDurvalumab
Shares Intermediate hepatocellular carcinoma (BCLC B), Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma, Hepatocellular carcinoma.
- IdeaDosimetry-personalised PRRT instead of four fixed cycles
Shares Dosimetry, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, SPECT & bone scan.
- TrialA US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat
Shares Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma, Hepatocellular carcinoma, Yttrium-90.
- TrialNETTER-1
Shares Erik S. Mittra, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Neuroendocrine tumours.
- TermPRRT (peptide receptor radionuclide therapy)
Shares Dosimetry, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Neuroendocrine tumours.